Instituto Mexicano del Seguro Social
León, Guanajuato, 37320, Mexico
NCT Number: NCT02041520
Introduction: Highly active antiretroviral therapy (HAART) has showed its effectiveness in the prevention of complications in seropositive for HIV patients. However, they develop some manifestations such as lipodystrophy, dyslipidemia, and glucose intolerance increasing cardiovascular risk.
Clinical trials in general population and in patients on hemodialysis have demonstrated a significant reduction in cardiovascular events using fish oil. Omega-3 fatty acids are believed to be beneficial in prevention of atherosclerosis reducing lipids levels specially triglycerides. Also in general populations it has been described a benefit effect of omega 3 acids on oxidative stress.
Objective: to know the effect of omega 3 acids on different markers of oxidative stress in seropositive HIV patients.
Methods: We will perform a randomized parallel controlled clinical trial in seropositive HIV patients from 20 to 55 years old on clinical score A1, A2, B1 or B2 who received HAART. They will be randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline anthropometric measurements, lipid profile, glucose and stress oxidative levels (nitric oxide, malondialdehyde, total glutathion, and lipid peroxidation products) will be evaluated.
Sample size was calculated according to different variables. We selected the biggest one calculated for a difference in nitric oxide of 25% after treatment between groups and a standard deviation (SD) value of 10µmol/L. Whit this information we obtained a sample size of 31 patients per group for an 80% statistical power with α= 0.05. Assuming a 15% patient lost, a sample size of 35 per group was considered.
Looking for future studies?
Notify Me20 year–60 year
All sexes
Interventional
Phase 3
León, Guanajuato, 37320, Mexico
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Other names: Zonelabs, Marblehead MA
olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Other names: olive oil
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Time frame: The difference of this value at 6 months in relation to baseline value
Coordinación de Investigación en Salud, Mexico
Other Gov
Effect of Omega 3 Fatty Acids on Oxidative Stress in Seropositive HIV Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05609513
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Kampala, Uganda
View Trial DetailsNCT06739915
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Soweto, Gauteng, South Africa
View Trial DetailsNCT04446611
Acquired Immunodeficiency Syndrome, Antenatal Care
East London, Eastern Cape, South Africa
View Trial DetailsNCT05121064
Acquired Immunodeficiency Syndrome, Alcohol-Related Disorders
Lusaka, Zambia
View Trial Details